Pelcitoclax

DB16285InvestigationalSmall molecule

Pelcitoclax is under investigation in clinical trial NCT04210037 (Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/refractory Small Cell Lung Cancer).

Mechanism: Pharmacologically active on Bcl-2-like protein 2, Bcl-2-like protein 1, and Apoptosis regulator Bcl-2
Curator reviewed
Formula / weight: C₅₇H₆₆ClF₄N₆O₁₁PS₄ · 1281.84 g/mol (avg)
Code names: APG-1252

Resolves to

Compound

UNII317UBD60MLCAS1619923-36-2

Structure

InChIKeyQIOCQCYXBYUYLH-YACUFSJGSA-NSMILES

CC(C)N1C(C)=C(C(=C1C1=CC=C(Cl)C=C1)C1=CC(=CC(F)=C1)N1CCN(CC1)C1=CC=C(NS(=O)(=O)C2=CC=C(N[C@H](CCN3CCC(CC3)C(=O)OCCCP(O)(O)=O)CSC3=CC=CC=C3)C(=C2)S(=O)(=O)C(F)(F)F)C=C1)S(C)(=O)=O

Targets

Q92843BCL2L2Q07817BCL2L1P49950Bcl2

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pelcitoclax, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account